Progressive licensing needs progressive open debate

Hébert, Paul C.
June 2007
CMAJ: Canadian Medical Association Journal;6/19/2007, Vol. 176 Issue 13, p1801
Academic Journal
The author reflects on the need for close examination on the progressive licensing of drugs by regulatory agencies in Canada. The author comments that pharmaceutical products cannot be easily approved and cannot be driven by profit. He points out that regulatory agencies must focus on a transparent, patient-centered regulatory system which ensures drugs are safe and efficacious before and after their release.


Related Articles

  • The House-Passed Prescription Drug Bill Still Faces Strong Obstacles in the Senate. Hess, Glenn // Chemical Market Reporter;07/03/2000, Vol. 258 Issue 1, p1 

    Discusses the status of the House-passed prescription drug bill in the United States. Supporters of the bill; Plan of United States President Bill Clinton to veto the bill; Reaction of drug manufacturers on the issue.

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;8/4/2003, Vol. 264 Issue 3, p8 

    Reports developments on approved drugs manufactured by pharmaceutical industry as of August 4, 2003 in the U.S.

  • NTI legislation expected in 1998.  // Drug Store News;11/17/97, Vol. 19 Issue 19, pCP4 

    Reports on the Arizona pharmacy board's call for all pharmacists in the state to familiarize themselves with all the issues surrounding narrow therapeutic index (NTI) drugs. Expected introduction of a legislation that limits the right of pharmacists to substitute generics for NTI drugs.

  • Drug patents and promotion: a trade off for Europe? Taylor, David // BMJ: British Medical Journal (International Edition);7/20/91, Vol. 303 Issue 6795, p151 

    Focuses on the impact of the pharmaceutical patent regulation on the pharmaceutical industry in Europe. Desire of the industry for longer patent terms; Provisions of the regulation; Impact of the regulation on industry competition.

  • Egypt.  // MEED: Middle East Economic Digest;2/21/1997, Vol. 41 Issue 8, p27 

    Reports on the Egyptian government's plans to modernize laws governing the pharmaceutical sector. Comments on the country's existing patent laws; Plans to open up the pharmaceutical market.

  • WEEK IN WASHINGTON.  // BioWorld Insight;10/26/2009, Vol. 17 Issue 43, p7 

    The article reports that the U.S. Senate Judiciary Committee passed a bill which prohibits pharmaceutical companies from compensating generic drugmakers to hold the launch of competitive products.

  • Likely inclusion of drugs in MRP net.  // Chemical Business;Aug97, Vol. 11 Issue 1, p49 

    States that the Finance minister of India is studying the question of bringing the pharmaceutical industry under the provision of levying excise on the basis of the maximum retail prices. Details of the provision.

  • PhRMA Takes Stand Against Affordable Prescription Bill.  // Chemical Market Reporter;10/04/99, Vol. 256 Issue 14, p9 

    Looks at the implication of the Affordable Prescription Drugs Act of 1999 in the United States on the brandname drug industry. Comments from Alan Holmer, president of the Pharmaceutical Research and Manufacturers of America.

  • Federal investigators target payments to formularies, docs. Weschler, Jill // Managed Healthcare Executive;Jun2003, Vol. 13 Issue 6, p10 

    Reports on a policy on lawful marketing of pharmaceuticals released by the Office of the Inspector General of the U.S. Health and Human Services Department targeting formulary committees, pharmacy benefit managers, pharmacists and physicians. Identification of drug industry practices most...

  • House votes to allow drug imports from abroad.  // Drug Topics;8/04/2003, Vol. 147 Issue 15, p5 

    Reports on the U.S. House's voice vote approving legislation to allow pharmacies, wholesalers and individuals to import drugs from abroad.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics